ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Ainos Inc

Ainos Inc (AIMD)

0.82
-0.009
(-1.09%)
Closed February 26 04:00PM
0.82
0.00
( 0.00% )
Pre Market: 05:00AM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

AIMD News

Official News Only

AIMD Discussion

View Posts
Bigguy4 Bigguy4 7 days ago
Like putting lipstick on a pig.....still a pig !!!!
👍️0
mlnman mlnman 2 weeks ago
$AIMD presented on virtual investor conference.
👍️0
Bigguy4 Bigguy4 4 weeks ago
13D filing discloses a lot of shares are freeing up under 144 sold at .185 per share. Guaranteed will be hitting the market to cover shorting going on now.
👍️0
Bigguy4 Bigguy4 4 weeks ago
Toxic notes are coming due, now registered , will flood the market with new shares soon
👍️0
Bigguy4 Bigguy4 1 month ago
Company just took out another 875k of toxic notes , companies with no cash should never be on nasdaq , company heading to OTC land.
👍️0
Bigguy4 Bigguy4 1 month ago
Convertible bonds coming due soon , will flood the market with new shares . Heading for penny stock land soon.
👍️0
Monksdream Monksdream 1 month ago
AIMD new 52 week low
👍️0
Bigguy4 Bigguy4 2 months ago
Obvious manipulation by market makers , how else does a company with less than 5 million in entire float trade 30 million . Run for the hills.
👍️0
subslover subslover 2 months ago
LOL that's what I wanna know too :)
👍️0
threebabiesbusy threebabiesbusy 2 months ago
Today's volume is off the charts....

Jan 04 2024 1.73 -0.24 -11.96% 1.88 1.95 1.60 100,643
Jan 03 2024 1.965 0.05 2.34% 1.95 2.00 1.8623 4,817
Jan 02 2024 1.92 -0.13 -6.34% 2.11 2.11 1.85 31,775
Dec 29 2023 2.05 0.00 0.0% 2.03 2.40 1.95 31,706
Dec 28 2023 2.05 0.08 4.33% 1.95 2.4414 1.95 111,157
Dec 27 2023 1.965 0.01 0.26% 1.96 2.2399 1.833 105,283
Dec 26 2023 1.96 0.01 0.51% 2.05 2.3356 1.9007 256,983
Dec 22 2023 1.95 -0.32 -14.16% 2.26 2.3798 1.7701 43,335
Dec 21 2023 2.2718 -0.23 -9.12% 2.36 2.64 2.1005 41,725
Dec 20 2023 2.4999 -0.11 -4.22% 2.55 2.6499 2.3001 9,725
Dec 19 2023 2.61 -0.34 -11.52% 2.81 2.86 2.61 5,769
Dec 18 2023 2.9499 -0.37 -11.15% 2.72 3.00 2.71 11,498
Dec 15 2023 3.32 0.54 19.43% 2.75 3.32 2.5124 26,167
Dec 14 2023 2.7799 0.08 3.15% 2.82 2.82 2.50 22,349
Dec 13 2023 2.695 -0.13 -4.58% 2.825 2.8375 2.695 3,288
Dec 12 2023 2.8245 -0.12 -4.16% 2.8505 2.95 2.60 4,022
Dec 11 2023 2.9471 0.00 0.07% 2.896 2.9495 2.85 1,744
Dec 08 2023 2.945 0.00 -0.17% 2.949 2.95 2.855 3,984
Dec 07 2023 2.95 0.00 0.0% 2.90 2.95 2.90 726
Dec 06 2023 2.95 0.00 0.0% 2.90 2.95 2.85 4,006
Dec 05 2023 2.95 0.08 2.63% 2.9675 2.9675 2.80 7,842
👍️0
threebabiesbusy threebabiesbusy 2 months ago
why the uptick?
👍️0
subslover subslover 2 months ago
Do you have a link to the news? tia
👍️0
Bigguy4 Bigguy4 2 months ago
This deal is doomed to fail.....news is about all the same subject , just shuffled around .
👍️0
Monksdream Monksdream 2 months ago
AIMD new 52 week low
👍️0
Bigguy4 Bigguy4 2 months ago
If this selling doesn't stop , this company will lose its nasdaq listing . Then we all will be screwed .
👍️0
Awl416 Awl416 3 months ago
Wild
👍️0
subslover subslover 7 months ago
nope
👍️0
DK11 DK11 7 months ago
Subs do you belong to WeBull?
👍️0
DK11 DK11 7 months ago
Sorry, Bud this train is going nowhere for today.
👍️0
subslover subslover 7 months ago
I'm out last night @ $1.60 for a quick 100%
👍️0
Invest-in-America Invest-in-America 7 months ago
AIMD: Let's go!!



PS: I'm in @FREQ too today; could be a decent one. (Trying to curtail my traditional childish posting.)
👍️0
harry crumb harry crumb 7 months ago
Typical pump up an premarket selloff, careful here, it’l go go down to the .70’s again, they all do
👍️0
AJ Freely AJ Freely 7 months ago
$AIMD - Up 76% Pre-Market/ Current Price $1.30
Company ramping up marketing of VELDONA® Pet & aiming to complete clinical trials in Taiwan of its flagship AI Nose-powered POCT by end of '23
👍️0
Monksdream Monksdream 7 months ago
Ainos Inc NASDAQ: AIMD*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap GrowthCompany profile
Ainos, Inc. is engaged in developing medical technologies for point-of-care (POCT) testing and medical treatment for a range of disease indications. The Company is engaged in the research and clinical development activities for its programs, securing related intellectual property, and commercializing therapeutics using low-dose non-injectable interferon (IFN). Its Medtech solutions includes COVID-19 Antigen Rapid Test Kit, Volatile Organic Compounds (VOC) POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha (VELDONA) and Synthetic RNA (SRNA). Its Ainos Flora device is intended to perform a non-invasive test for female vaginal health and certain common sexually transmitted diseases (STDs). Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia.
👍️0
subslover subslover 8 months ago
It pays to buy the best.
👍️0
Triple nickle Triple nickle 8 months ago
Now we’re talkin
👍️0
subslover subslover 11 months ago
Huge gains today on 51 million shares traded.
👍️0
subslover subslover 11 months ago
Here ya go === https://www.streetinsider.com/Corporate+News/Ainos+%28AIMD%29%2C+Merdury+Sign+MoU+to+Explore+Phase+3+Study+of+VELDONA+Drug+Candidate+for+Treatment+of+Oral+Warts+in+HIV-Seropositive+Patients/21366603.html
👍️0
Awl416 Awl416 11 months ago
News?
👍️0
Invest-in-America Invest-in-America 1 year ago
THANKS AGAIN, T-B-T-9460!!
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 1 year ago
$AIMD Strong bottom bounce here..and check out that gap to will..adding to my watchlist for next week..

https://stockcharts.com/c-sc/sc?s=AIMD&p=D&b=5&g=0&i=0&r=1664637452592
👍️0
subslover subslover 1 year ago
Any time bro!
👍️0
Invest-in-America Invest-in-America 1 year ago
THANKS!!!
👍️0
subslover subslover 1 year ago
Ainos announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2. The company’s results showed that its low-dose oral interferon alpha (“IFN-a”) formulation, VELDONA, had a therapeutic effect on lungs infected with the SARS-CoV-2 (the Omicron variant) virus by regulating the immune response, thus expediting recovery of infected animals. Plus the company has submitted the application documents for U.S. FDA Phase 2 clinical trials for evaluating the efficacy of VELDONA in patients with mild COVID-19.

The study evaluated the effectiveness of VELDONA over a 16-day course (5-day pre-treatment, one-day during viral infection and ten-day treatment after infection) of Omicron-variant-infected hamsters. Compared with hamsters in the placebo group receiving solution without VELDONA (the Placebo Group), the hamsters in the group receiving solution with VELDONA demonstrated resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days. The body weights of the hamsters in the VELDONA Group remained more stable than those of the hamsters in the Placebo Group during the treatment period.
👍️0
Invest-in-America Invest-in-America 2 years ago
THOSE WARRANTS: Lord EZ!! I grabbed $5K worth at $0.48 this morning --- circa 10:00 a.m. (ET); heck, just a 'Lotto' play, from YOUR perspective! However, neither the Markets, nor my E-Turd acct., are displaying any 'increase', per se, in PRICE of my WARRANTS thereof. WEIRD!!

👍️0
makinezmoney makinezmoney 2 years ago
$AIMDW: Woahhhhhhhhhhh.............. how many you get amigo ????

Howd I miss this ??

You are scaring me with all your early watches


Awesome stuff



GO $AIMDW
👍️0
Invest-in-America Invest-in-America 2 years ago
AIMDW: Hey, but watch its WARRANTS, Buckos!!! (HA-HA!!) Just might SPOOK-ya!!!

👍️0
Renee Renee 2 years ago
AIMD moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
Renee Renee 2 years ago
AIMD one for 15 reverse split. PPS closed at .72

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Renee Renee 3 years ago
Amarillo Biosciences Inc., AMAR, changed to AINOS Inc., AIMD:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Alpine600 Alpine600 3 years ago
I see that company name change is already reflected on my brokerage account and I now hold Ainos Inc. If you haven’t already checked out their website it’s worth a look. They are a subsidiary of Taiwan Carbon Nano Technology Corp. From a corporate governance and operations standpoint this represents a big improvement in my view. I had kind of written this investment off (long term holder) but I’m actually pretty excited again about potential.
👍️0
ANTI-BAGHOLDER ANTI-BAGHOLDER 3 years ago
This could be pretty big!
👍️0
ANTI-BAGHOLDER ANTI-BAGHOLDER 3 years ago
AMAR interesting news Change of control

https://www.accesswire.com/641597/Amarillo-Biosciences-Inc-Announced-Closing-under-Securities-Purchase-Agreement-with-Majority-Investor-and-Name-Change-to-Ainos-Inc
👍️0
MADDSTACKER MADDSTACKER 3 years ago
Sorry that was total owned ..
👍️0
MADDSTACKER MADDSTACKER 3 years ago
Insiders buying 150 k in stock
👍️0
GreenKnight GreenKnight 3 years ago
This thing is going to fly. $AMAR
👍️0
adijas adijas 3 years ago
Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board

Amarillo, TX, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University of Western Australia and renown pioneer in interferon research, to the Company’s Scientific Advisory Board.

Based on the Company’s past successful clinical research using low-dose interferon, Dr. Beilharz will work closely with ABI and its research collaborators in initiating several clinical trials this year. These trials will primarily be focused on developing a therapeutic for COVID-19, as well as the continuation of the Company’s late-stage treatments for thrombocytopenia and Sjögren’s syndrome. ABI Chairman & CEO, Dr. Stephen T. Chen, remarked, “We are excited to be working again with Dr. Beilharz who has contributed tremendously to the interferon research field and there is a high degree of confidence that our non-injectable interferon development program, Veldona, will prove to be an effective therapeutic for these targeted indications based on supporting clinical research.”

In relation to COVID-19, clinical data has shown low-dose interferon alpha effective against other coronaviruses such as H1N1 and SARS. Previously, a published study for a collaborative phase 2b influenza trial conducted by Dr. Beilharz, “Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an in?uenza pandemic year” demonstrated 150 IU interferon alpha delivered orally with ABI’s proprietary formulated Veldona lozenge significantly reduced the severity of symptoms in males aged 50 years or more and showed potential to enhance vaccine-induced protection against influenza. Other published clinical and non-clinical studies confirm low-dose interferon’s unique mechanism of action provide the medical-scientific rationale for ABI’s clinical development strategy for Veldona. Applying clinical studies towards COVID-19 is a logical next step.

Dr. Beilharz has stated, “The current COVID-19 pandemic urgently requires prevention and treatment options, particularly for frontline medical staff and at-risk groups, and oral low-dose type 1 interferon is a readily available public health option with an extensive published literature. It’s exciting that in the Hubei Province in China, where this pandemic originated, they have released details of a study where they treated over 2,000 frontline medical workers with oral interferon nose drops to try and protect them. There have been no reports of any contracting COVID-19, while in the controls - another 2,000 nurses and doctors working in the same province - 50 to 60 per cent were infected with COVID-19. That is a pretty clear demonstration of the prophylactic value of this.” Dr. Beilharz will be managing the Company’s COVID-19 clinical trials in Australia.

ABI is also preparing to resume its clinical trials for thrombocytopenia, an immune condition causing low platelet count prevalent in patients that experience hepatitis-C relapse and other debilitating conditions such as chemotherapy treatment. In a 2014 published study, “A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse,” Dr. Chau-Ting Yeh, Director, Liver Research Center at Chang Gung Memorial Hospital (Taiwan), was the co-author and principal investigator for a phase 2 clinical trial in which it was discovered that 500 IU low-dose interferon alpha was surprisingly effective in exerting a significantly expedited recovery of platelet count in chronic hepatitis C patients having moderate to severe liver fibrosis. As a result of this study ABI applied for and received four thrombocytopenia related patents. Dr. Yeh will be managing the Company’s subsequent thrombocytopenia clinical trials in Taiwan.

“As we move forward with planned Veldona clinical trials, both Dr. Beilharz and Dr. Yeh’s decades of research experience will be critical in successful execution and the establishment of effective collaborations with other stakeholders. Our goal will be to diligently advance the Veldona clinical trial program with the vision of developing Veldona-based new treatments for COVID-19 patients, as well as patients with difficult-to-treat indications like thrombocytopenia and autoimmune disorders such as Sjögren’s syndrome who are in urgent need for therapeutic solutions,” said Dr. Stephen T. Chen.

About Dr. Manfred Beilharz

A leader in interferon research, Dr. Beilharz has extensive knowledge of type-1 interferons in relation to diseases of viral, autoimmune and neoplastic origin, as well as principal investigator experience in numerous interferon research studies including previous collaboration with ABI in an oral low-dose interferon alpha “Winter Colds and Flu” phase IIb clinical trial in Perth, Western Australia (2008-2010). Dr. Beilharz serves on the scientific advisory boards of US and Australian Biotech companies, consults widely, and is on the editorial board of the “Journal of Interferon and Cytokine Research.” He has worked full time in biomedical research since 1982 holding posts at Monash University, the University of Western Australia, Johns Hopkins University, Oxford University and the Australian Neuromuscular Research Institute.

About Dr. Chau-Ting Yeh

Dr. Yeh is currently a Director of the Liver Research Center at Chang Gung Memorial Hospital and is a leading researcher in hepatology with extensive experience in molecular biology and treatment of hepatitis B and hepatitis C, Hepatocarcinogenesis and marker-guided anticancer treatment. His ground-breaking research publication “Efficacy of Low Dose Oral Interferon-alpha in Preventing Hepatitis C Relapse” was instrumental in ABI obtaining its current patents related to thrombocytopenia. Dr. Yeh has an M.D. from National Taiwan University, Medical School and Ph.D. from USC, Department of Internal Molecular Microbiology and Immunology. He has received numerous awards including Distinguished Research Faculty Member, Chang Gung University (2012) and Taiwan Ministry of Science & Technology, FutureTech Demo and Breakthrough Award (2019).
👍️0
GreenKnight GreenKnight 3 years ago
$AMAR - I like this - https://www.globenewswire.com/news-release/2020/09/10/2092023/0/en/Amarillo-Biosciences-to-Initiate-Low-Dose-Interferon-Clinical-Trials-to-Treat-COVID-19-Appoints-Interferon-Specialist-Dr-Manfred-Beilharz-to-Scientific-Advisory-Board.html
👍️0
Quintessence Quintessence 5 years ago
Another Form 4.
👍️0
Quintessence Quintessence 5 years ago
Several form 4s out recently. Hoping PPS can move up from here.
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com